Exelon Patch 10 Transdermal Flaster Kullanma Talimat. Sinir Sistemi Psikoanaleptikler Anti Demans lalarAlzheimer lalar Antikolinesterazlar. Notasprensa Exelon Patch, la primera terapia transdrmica para la enfermedad de Alzheimer, puede constituir un nuevo y prometedor modo de tratamiento de la demencia. Alzheimer disease AD is an acquired disorder of cognitive and behavioral impairment that markedly interferes with social and occupational functioning. It is an. A transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Exelon Patch FDA prescribing information, side effects and uses     Alzheimers Disease. Exelon Patch is indicated for the treatment of dementia of the Alzheimers type AD. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimers disease. Parkinsons Disease Dementia. Exelon Patch is indicated for the treatment of mild to moderate dementia associated with Parkinsons disease PDD. DOSAGE AND ADMINISTRATION     Recommended Dosing. Initial Dose. Initiate treatment with one 4. Exelon Patch applied to the skin once daily see Dosage and Administration 2. Dose Titration. Increase the dose only after a minimum of 4 weeks at the previous dose, and only if the previous dose has been tolerated. For mild to moderate AD and PDD patients, continue the effective dose of 9. Patients can then be increased to the maximum effective dose of 1. For patients with severe AD, 1. Doses higher than 1. Warnings and Precautions 5. Adverse Reactions 6. Mild to Moderate Alzheimers Disease and Mild to Moderate Parkinsons Disease Dementia. The effective dosage of Exelon Patch is 9. Severe Alzheimers Disease. The effective dosage of Exelon Patch in patients with severe Alzheimers disease is 1. Interruption of Treatment. If dosing is interrupted for 3 days or fewer, restart treatment with the same or lower strength Exelon Patch. If dosing is interrupted for more than 3 days, restart treatment with the 4. Exelon Patch and titrate as described above. Dosing in Specific Populations. Alvogen has launched the first generic equivalent of Exelon patch rivastigmine transdermal system in the United States. The product will be marketed by Alvogen in. PARKINSONISM TREATMENTS Generic Brand Form Strength Adult Dose ANTICHOLINERGICS benztropine scored tabs 0. Initially 0. 51mg at bedtime. More. Copyright 2008 by Therapeutic Research Center Pharmacists Letter Prescribers Letter P. O. Box 8190, Stockton, CA 95208 Phone 2094722240. Exelon rivastigmine is used to treat dementia caused by Alzheimers or Parkinsons disease. Includes Exelon side effects, interactions and indications. T800x600/201506558388491fc3a.jpg' alt='Rivastigmine Exelon Patch 5' title='Rivastigmine Exelon Patch 5' />Dosing Modifications in Patients with Hepatic Impairment. Consider using the 4. Exelon Patch as both the initial and maintenance dose in patients with mild Child Pugh score 5 to 6 to moderate Child Pugh score 7 to 9 hepatic impairment see Use in Specific Populations 8. Clinical Pharmacology 1. Dosing Modifications in Patients with Low Body Weight. Carefully titrate and monitor patients with low body weight lt 5. Exelon Patch if such toxicities develop. Switching to Exelon Patch from Exelon Capsules or Exelon Oral Solution. Patients treated with Exelon Capsules or Oral Solution may be switched to Exelon Patch as follows A patient who is on a total daily dose of lt 6 mg of oral rivastigmine can be switched to the 4. Exelon Patch. A patient who is on a total daily dose of 6 mg to 1. Exelon Patch. Instruct patients or caregivers to apply the first patch on the day following the last oral dose. Important Administration Instructions. Exelon Patch is for transdermal use on intact skin. Do not use the patch if the pouch seal is broken or the patch is cut, damaged, or changed in any way. Ultimate Spider Man Game Full Version. Apply the Exelon Patch once a day. Press down firmly for 3. Use the upper or lower back as the site of application because the patch is less likely to be removed by the patient. If sites on the back are not accessible, apply the patch to the upper arm or chest. Do not apply to a skin area where cream, lotion, or powder has recently been applied. Do not apply to skin that is red, irritated, or cut. Replace the Exelon Patch with a new patch every 2. Instruct patients to only wear 1 patch at a time remove the previous days patch before applying a new patch see Warnings and Precautions 5. Overdosage 1. 0. If a patch falls off or if a dose is missed, apply a new patch immediately and then replace this patch the following day at the usual application time. Change the site of patch application daily to minimize potential irritation, although a new patch can be applied to the same general anatomic site e. Do not apply a new patch to the same location for at least 1. May wear the patch during bathing and in hot weather. But avoid long exposure to external heat sources excessive sunlight, saunas, solariums. Place used patches in the previously saved pouch and discard in the trash, away from pets or children. Wash hands with soap and water after removing the patch. In case of contact with eyes or if the eyes become red after handling the patch, rinse immediately with plenty of water and seek medical advice if symptoms do not resolve. DOSAGE FORMS AND STRENGTHSExelon Patch is available in 3 strengths. Each patch has a beige backing layer labeled as either EXELON PATCH 4. AMCXEXELON PATCH 9. BHDIEXELON PATCH 1. CNFU    CONTRAINDICATIONSExelon Patch is contraindicated in patients with known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation see Description 1. Warnings and Precautions 5. Isolated cases of generalized skin reactions have been described in postmarketing experience see Adverse Reactions 6. WARNINGS AND PRECAUTIONS     Medication Errors Resulting in Overdose Medication errors with Exelon Patch have resulted in serious adverse reactions some cases have required hospitalization, and rarely, led to death. The majority of medication errors have involved not removing the old patch when putting on a new one and the use of multiple patches at one time. Instruct patients and their caregivers on important administration instructions for Exelon Patch see Dosage and Administration 2. Gastrointestinal Adverse Reactions. Exelon Patch can cause gastrointestinal adverse reactions, including significant nausea, vomiting, diarrhea, anorexiadecreased appetite, and weight loss. Dehydration may result from prolonged vomiting or diarrhea and can be associated with serious outcomes. The incidence and severity of these reactions are dose related see Adverse Reactions 6. For this reason, initiate treatment with Exelon Patch at a dose of 4. Dosage and Administration 2. If treatment is interrupted for more than 3 days because of intolerance, reinitiate Exelon Patch with the 4. A postmarketing report described a case of severe vomiting with esophageal rupture following inappropriate reinitiation of treatment of an oral formulation of rivastigmine without retitration after 8 weeks of treatment interruption. Inform caregivers to monitor for gastrointestinal adverse reactions and to inform the physician if they occur. It is critical to inform caregivers that if therapy has been interrupted for more than 3 days because of intolerance, the next dose should not be administered without contacting the physician regarding proper retitration. Skin Reactions. Skin application site reactions may occur with Exelon Patch These reactions are not in themselves an indication of sensitization. However, use of rivastigmine patch may lead to allergic contact dermatitis. Allergic contact dermatitis should be suspected if application site reactions spread beyond the patch size, if there is evidence of a more intense local reaction e. In these cases, treatment should be discontinued see Contraindications 4. In patients who develop application site reactions to Exelon Patch suggestive of allergic contact dermatitis and who still require rivastigmine, treatment should be switched to oral rivastigmine only after negative allergy testing and under close medical supervision. It is possible that some patients sensitized to rivastigmine by exposure to rivastigmine patch may not be able to take rivastigmine in any form. There have been isolated postmarketing reports of patients experiencing disseminated allergic dermatitis when administered rivastigmine irrespective of the route of administration oral or transdermal. In these cases, treatment should be discontinued see Contraindications 4.